Shilpa Medicare has received approval from its board for the sale of biological unit by way of slump sale to Shilpa Biologicals, a wholly owned subsidiary of the company subject to the approval of shareholders. The biological unit proposed to be sold is under construction/installation stage and not yet commenced commercial operations.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
